Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Clinical Oral Investigations
Erschienen in: Clinical Oral Investigations 9/2018

16.02.2018 | Original Article

Bone mineralization and vascularization in bisphosphonate-related osteonecrosis of the jaw: an experimental study in the rat

verfasst von: Jean-Daniel Kün-Darbois, Hélène Libouban, Guillaume Mabilleau, Florence Pascaretti-Grizon, Daniel Chappard

Erschienen in: Clinical Oral Investigations | Ausgabe 9/2018

Einloggen, um Zugang zu erhalten

Abstract

Objectives

Pathogenesis of bisphosphonate-related osteonecrosis of the jaws (BRONJ) is not fully explained. An antiangiogenic effect of bisphosphonates (BPs) or an altered bone quality have been advocated. The aims of the present study were to analyze alveolar mandibular vascularization and bone quality in rats with BRONJ.

Materials and methods

Thirty-eight Sprague-Dawley rats were randomized into two groups: zoledronic acid (ZA), n = 27, and control (CTRL) n = 11. The ZA group received a weekly IV injection of ZA (100 μg/kg) during 10 weeks. The CTRL group received saline. After 6 weeks, extraction of the right mandibular molars was performed. Rats were sacrificed after 14 weeks. Microtomography characterized bone lesions and vascularization after injection of a radio-opaque material. Raman microspectroscopy evaluated bone mineralization.

Results

Fifty-five percent of ZA rats presented bone exposure and signs of BRONJ. None sign was found at the left hemimandible in the ZA group and in the CTRL group. Vascular density appeared significantly increased in the right hemimandibles of the CTRL group compared to the left hemimandibles. Vascularization was reduced in the ZA group. A significantly increased of the mineral-to-amide ratio was found in the alveolar bone of ZA rats by Raman microspectroscopy.

Conclusions

In a rat model of BRONJ, microtomography evidenced osteonecrosis in BRONJ. Raman spectroscopy showed an increased mineralization. Vascularization after tooth extraction was impaired by ZA.

Clinical relevance

Prolonged BP administration caused an increase in the mineralization and a quantitative reduction of the vascularization in the alveolar bone; both factors might be involved concomitantly in the BRONJ pathophysiology.
Literatur
1.
Russell RGG (2011) Bisphosphonates: the first 40 years. Bone 49:2–19CrossRef
2.
Harrington JT, Ste-Marie LG, Brandi ML, Civitelli R, Fardellone P, Grauer A, Barton I, Boonen S (2004) Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int 74:129–135CrossRef
3.
Pols HA, Felsenberg D, Hanley DA et al (1999) Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int 9:461–468CrossRef
4.
Terpos E (2012) Bisphosphonate anticancer activity in multiple myeloma. Anti Cancer Agents Med Chem 12:123–128CrossRef
5.
Musto P, Petrucci MT, Bringhen S et al (2008) A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma. Cancer 113:1588–1595CrossRef
6.
Wang J, Goodger NM, Pogrel MA (2003) Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg 61:1104–1107CrossRef
7.
Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61:1115–1117CrossRef
8.
Rachner TD, Platzbecker U, Felsenberg D, Hofbauer LC (2013) Osteonecrosis of the jaw after osteoporosis therapy with denosumab following long-term bisphosphonate therapy. Mayo Clin Proc 88:418–419CrossRef
9.
Ruggiero S (2014) Osteonecrosis of the jaw: BRONJ and ARONJ. Fac Dent J 5:90–93CrossRef
10.
Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B, Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws AAoOMS (2009) American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw - 2009 update. Aust Endodont J 35:119–130CrossRef
11.
Ruggiero SL, Mehrotra B (2009) Bisphosphonate-related osteonecrosis of the jaw: diagnosis, prevention, and management. Annu Rev Med 60:85–96CrossRef
12.
Vahtsevanos K, Kyrgidis A, Verrou E et al (2009) Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol 27:5356–5362CrossRef
13.
Walter C, Al-Nawas B, Frickhofen N, Gamm H, Beck J, Reinsch L, Blum C, Grotz KA, Wagner W (2010) Prevalence of bisphosphonate associated osteonecrosis of the jaws in multiple myeloma patients. Head Face Med 6:11CrossRef
14.
Migliorati CA, Woo SB, Hewson I, Barasch A, Elting LS, Spijkervet FK, Brennan MT (2010) A systematic review of bisphosphonate osteonecrosis (BON) in cancer. Supp Care Cancer 18:1099–1106CrossRef
15.
Woo SB, Hellstein JW, Kalmar JR (2006) Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144:753–761CrossRef
16.
Marx RE, Cillo JE Jr, Ulloa JJ (2007) Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 65:2397–2410CrossRef
17.
Marx RE, Sawatari Y, Fortin M, Broumand V (2005) Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63:1567–1575CrossRef
18.
Boonyapakorn T, Schirmer I, Reichart PA, Sturm I, Massenkeil G (2008) Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol 44:857–869CrossRef
19.
Diz P, Scully C, Sanz M (2013) Dental implants in the medically compromised patient. J Dent 41:195–206CrossRef
20.
Kwon T-G, Lee C-O, Park J-W, Choi S-Y, Rijal G, Shin H-I (2014) Osteonecrosis associated with dental implants in patients undergoing bisphosphonate treatment. Clin Oral Implants Res 25:632–640CrossRef
21.
Ata-Ali J, Ata-Ali F, Peñarrocha-Oltra D, Galindo-Moreno P (2016) What is the impact of bisphosphonate therapy upon dental implant survival? A systematic review and meta-analysis. Clin Oral Implants Res 27:e38–e46CrossRef
22.
Rasmusson L, Abtahi J (2014) Bisphosphonate associated osteonecrosis of the jaw: an update on pathophysiology, risk factors, and treatment. Int J Dent 2014:471035CrossRef
23.
Cardemil C, Thomsen P, Larsson Wexell C (2015) Jaw bone samples from bisphosphonate-treated patients: a pilot cohort study. Clin Implant Dent Relat Res 17(Suppl 2):e679–e691CrossRef
24.
Voss PJ, Poxleitner P, Schmelzeisen R, Stricker A, Semper-Hogg W (2017) Update MRONJ and perspectives of its treatment. J Stomatol Oral Maxillofac Surg 118:232–235CrossRef
25.
Pabst AM, Ziebart T, Ackermann M, Konerding MA, Walter C (2014) Bisphosphonates' antiangiogenic potency in the development of bisphosphonate-associated osteonecrosis of the jaws: influence on microvessel sprouting in an in vivo 3D Matrigel assay. Clin Oral Invest 18:1015–1022CrossRef
26.
Petcu EB, Ivanovski S, Wright RG, Slevin M, Miroiu RI, Brinzaniuc K (2012) Bisphosphonate-related osteonecrosis of jaw (BRONJ): an anti-angiogenic side-effect? Diagn Pathol 7:78CrossRef
27.
Sharma D, Ivanovski S, Slevin M, Hamlet S, Pop TS, Brinzaniuc K, Petcu EB, Miroiu RI (2013) Bisphosphonate-related osteonecrosis of jaw (BRONJ): diagnostic criteria and possible pathogenic mechanisms of an unexpected anti-angiogenic side effect. Vascular cell 5:1CrossRef
28.
Wehrhan F, Stockmann P, Nkenke E, Schlegel KA, Guentsch A, Wehrhan T, Neukam FW, Amann K (2011) Differential impairment of vascularization and angiogenesis in bisphosphonate-associated osteonecrosis of the jaw-related mucoperiosteal tissue. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 112:216–221CrossRef
29.
Stresing V, Fournier PG, Bellahcene A, Benzaid I, Monkkonen H, Colombel M, Ebetino FH, Castronovo V, Clezardin P (2011) Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase. Bone 48:259–266CrossRef
30.
Im G-I, Jeong S-H (2015) Pathogenesis, management and prevention of atypical femoral fractures. J Bone Metab 22:1–8CrossRef
31.
Reid IR, Bolland MJ, Grey AB (2007) Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity? Bone 41:318–320CrossRef
32.
Russmueller G, Seemann R, Weiss K, Stadler V, Speiss M, Perisanidis C, Fuereder T, Willinger B, Sulzbacher I, Steininger C (2016) The association of medication-related osteonecrosis of the jaw with Actinomyces spp. infection. Sci Rep 6:31604CrossRef
33.
Sharma D, Hamlet S, Petcu E, Ivanovski S (2013) Animal models for bisphosphonate-related osteonecrosis of the jaws—an appraisal. Oral Dis 19:747–754CrossRef
34.
Sarkarat F, Kalantar Motamedi MH, Jahanbani J, Sepehri D, Kahali R, Nematollahi Z (2014) Platelet-rich plasma in treatment of zoledronic acid-induced bisphosphonate-related osteonecrosis of the jaws. Trauma Mon 19:e17196CrossRef
35.
Tsurushima H, Kokuryo S, Sakaguchi O, Tanaka J, Tominaga K (2013) Bacterial promotion of bisphosphonate-induced osteonecrosis in Wistar rats. Int J Oral Maxillofac Surg 42:1481–1487CrossRef
36.
Li CL, Lu WW, Seneviratne CJ, Leung WK, Zwahlen RA, Zheng LW (2016) Role of periodontal disease in bisphosphonate-related osteonecrosis of the jaws in ovariectomized rats. Clin Oral Implants Res 27:1–6CrossRef
37.
Akkus O, Polyakova-Akkus A, Adar F, Schaffler MB (2003) Aging of microstructural compartments in human compact bone. J Bone Miner Res 18:1012–1019CrossRef
38.
Roschger P, Fratzl P, Eschberger J, Klaushofer K (1998) Validation of quantitative backscattered electron imaging for the measurement of mineral density distribution in human bone biopsies. Bone 23:319–326CrossRef
39.
Mabilleau G, Mieczkowska A, Libouban H, Simon Y, Audran M, Chappard D (2015) Comparison between quantitative X-ray imaging, dual energy X-ray absorptiometry and microCT in the assessment of bone mineral density in disuse-induced bone loss. J Musculoskel Neuronal Interact 15:42–52
40.
Nyangoga H, Mercier P, Libouban H, Basle MF, Chappard D (2011) Three-dimensional characterization of the vascular bed in bone metastasis of the rat by microcomputed tomography (MicroCT). PLoSOne 6:e17336CrossRef
41.
Abtahi J, Agholme F, Aspenberg P (2013) Prevention of osteonecrosis of the jaw by mucoperiosteal coverage in a rat model. Int J Oral Maxillofac Surg 42:632–636CrossRef
42.
Pautke C, Kreutzer K, Weitz J, Knodler M, Munzel D, Wexel G, Otto S, Hapfelmeier A, Sturzenbaum S, Tischer T (2012) Bisphosphonate related osteonecrosis of the jaw: A minipig large animal model. Bone 51:592–599CrossRef
43.
Marino KL, Zakhary I, Abdelsayed RA, Carter JA, O'Neill JC, Khashaba RM, Elsalanty M, Stevens MR, Borke JL (2012) Development of a rat model of bisphosphonate-related osteonecrosis of the jaw (BRONJ). J Oral Implantol 38 Spec No:511–518CrossRef
44.
Abtahi J, Agholme F, Sandberg O, Aspenberg P (2012) Bisphosphonate-induced osteonecrosis of the jaw in a rat model arises first after the bone has become exposed. No primary necrosis in unexposed bone. J Oral Pathol Med 41:494–499CrossRef
45.
Biasotto M, Chiandussi S, Zacchigna S et al (2010) A novel animal model to study non-spontaneous bisphosphonates osteonecrosis of jaw. J Oral Pathol Med 39:390–396PubMed
46.
Hoff AO, Toth BB, Altundag K et al (2008) Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 23:826–836CrossRef
47.
Aguirre JI, Akhter MP, Kimmel DB, Pingel JE, Williams A, Jorgensen M, Kesavalu L, Wronski TJ (2012) Oncologic doses of zoledronic acid induce osteonecrosis of the jaw-like lesions in rice rats (Oryzomys palustris) with periodontitis. J Bone Miner Res 27:2130–2143CrossRef
48.
Mavrokokki T, Cheng A, Stein B, Goss A (2007) Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 65:415–423CrossRef
49.
Bamias A, Kastritis E, Bamia C et al (2005) Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23:8580–8587CrossRef
50.
Hokugo A, Christensen R, Chung EM, Sung EC, Felsenfeld AL, Sayre JW, Garrett N, Adams JS, Nishimura I (2010) Increased prevalence of bisphosphonate-related osteonecrosis of the jaw with vitamin D deficiency in rats. J Bone Miner Res 25:1337–1349CrossRef
51.
Mitsimponas K, Moest T, Iliopoulos C, Rueger T, Mueller C, Lutz R, Shakib K, Neukam F, Schlegel K (2016) Search for a reliable model for bisphosphonate-related osteonecrosis of the jaw: establishment of a model in pigs and description of its histomorphometric characteristics. Br J Oral Maxillofac Surg 54:883–888CrossRef
52.
Ersan N, van Ruijven LJ, Bronckers AL, Olgac V, Ilguy D, Everts V (2013) Teriparatide and the treatment of bisphosphonate-related osteonecrosis of the jaw: a rat model. Dentomaxillofac Radiol 43:20130144CrossRef
53.
Aghaloo TL, Kang B, Sung EC, Shoff M, Ronconi M, Gotcher JE, Bezouglaia O, Dry SM, Tetradis S (2011) Periodontal disease and bisphosphonates induce osteonecrosis of the jaws in the rat. J Bone Miner Res 26:1871–1882CrossRef
54.
Pacheco VN, Langie R, Etges A, Ponzoni D, Puricelli E (2015) Nitrogen-containing bisphosphonate therapy: assessment of the alveolar bone structure in rats—a blind randomized controlled trial. Int J Exp Pathol 96:255–260CrossRef
55.
Russell RGG, Watts NB, Ebetino FH, Rogers MJ (2008) Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 19:733–759CrossRef
56.
Juillard A, Falgayrac G, Cortet B, Vieillard M-H, Azaroual N, Hornez J-C, Penel G (2010) Molecular interactions between zoledronic acid and bone: an in vitro Raman microspectroscopic study. Bone 47:895–904CrossRef
57.
Olejnik C, Falgayrac G, During A, Cortet B, Penel G (2016) Doses effects of zoledronic acid on mineral apatite and collagen quality of newly-formed bone in the rat's calvaria defect. Bone 89:32–39CrossRef
58.
Boanini E, Gazzano M, Bigi A (2012) Time course of zoledronate interaction with hydroxyapatite nanocrystals. J Phys Chem C 116:15812–15818CrossRef
59.
Misof BM, Roschger P, Gabriel D, Paschalis EP, Eriksen EF, Recker RR, Gasser JA, Klaushofer K (2013) Annual intravenous zoledronic acid for three years increased cancellous bone matrix mineralization beyond normal values in the HORIZON biopsy cohort. J Bone Miner Res 28:442–448CrossRef
60.
Vermeer J, Renders G, Duin M, Jansen I, Bakker L, Kroon S, Vries T, Everts V (2017) Bone-site-specific responses to zoledronic acid. Oral Dis 23:126–133CrossRef
61.
Verzola MHA, Frizzera F, de Oliveira GJPL, Pereira RMR, Rodrigues-Filho UP, Nonaka KO, Orrico SRP (2015) Effects of the long-term administration of alendronate on the mechanical properties of the basal bone and on osseointegration. Clin Oral Implants Res 26:1466–1475CrossRef
62.
Huebsch RF, Coleman RD, Frandsen AM, Becks H (1952) The healing process following molar extraction. I. Normal male rats (long-evans strain). Oral Surg Oral Med Oral Pathol 5:864–876CrossRef
63.
Fournier P, Boissier S, Filleur S, Guglielmi J, Cabon F, Colombel M, Clezardin P (2002) Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 62:6538–6544PubMed
64.
Tang X, Zhang Q, Shi S, Yen Y, Li X, Zhang Y, Zhou K, Le AD (2010) Bisphosphonates suppress insulin-like growth factor 1-induced angiogenesis via the HIF-1alpha/VEGF signaling pathways in human breast cancer cells. Int J Cancer 126:90–103CrossRef
65.
Allegra A, Alonci A, Penna G et al (2010) Bisphosphonates induce apoptosis of circulating endothelial cells in multiple myeloma patients and in subjects with bisphosphonate-induced osteonecrosis of the jaws. Acta Haematol 124:79–85CrossRef
66.
Allegra A, Oteri G, Nastro E et al (2007) Patients with bisphosphonates-associated osteonecrosis of the jaw have reduced circulating endothelial cells. Hematol Oncol 25:164–169CrossRef
67.
Bi Y, Gao Y, Ehirchiou D, Cao C, Kikuiri T, Le A, Shi S, Zhang L (2010) Bisphosphonates cause osteonecrosis of the jaw-like disease in mice. Am J Pathol 177:280–290CrossRef
68.
Sigua-Rodriguez EA, da Costa RR, de Brito AC, Alvarez-Pinzon N, de Albergaria-Barbosa JR (2014) Bisphosphonate-related osteonecrosis of the jaw: a review of the literature. Int J Dent 2014:192320CrossRef
Metadaten
Titel
Bone mineralization and vascularization in bisphosphonate-related osteonecrosis of the jaw: an experimental study in the rat
verfasst von
Jean-Daniel Kün-Darbois
Hélène Libouban
Guillaume Mabilleau
Florence Pascaretti-Grizon
Daniel Chappard
Publikationsdatum
16.02.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
Clinical Oral Investigations / Ausgabe 9/2018
Print ISSN: 1432-6981
Elektronische ISSN: 1436-3771
DOI
https://doi.org/10.1007/s00784-018-2385-2

Weitere Artikel der Ausgabe 9/2018

Clinical Oral Investigations 9/2018 Zur Ausgabe

Original Article

Microbiological analysis and the outcomes of periodontal treatment with or without adjunctive systemic antibiotics—a retrospective study

Original Article

Oral health in Alzheimer’s disease: a multicenter case-control study

Original Article

Allogeneic bone block for challenging augmentation—a clinical, histological, and histomorphometrical investigation of tissue reaction and new bone formation

Original Article

The use of throat packs in pediatric cleft lip/palate surgery: a retrospective study

Review

The potential association between periodontitis and non-alcoholic fatty liver disease: a systematic review

Original Article

Effect of multiple autoclave cycles on the surface roughness of HyFlex CM and HyFlex EDM files: an atomic force microscopy study

Neu im Fachgebiet Zahnmedizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

19.04.2024 Vorhofflimmern Nachrichten

Werden Personen mit Vorhofflimmern in der Blanking-Periode nach einer Katheterablation gegen eine bestehende Parodontitis behandelt, verbessert dies die Erfolgsaussichten. Dafür sprechen die Resultate einer prospektiven Untersuchung.

Invasive Zahnbehandlung: Wann eine Antibiotikaprophylaxe vor infektiöser Endokarditis schützt

11.04.2024 Endokarditis Nachrichten

Bei welchen Personen eine Antibiotikaprophylaxe zur Prävention einer infektiösen Endokarditis nach invasiven zahnärztlichen Eingriffen sinnvoll ist, wird diskutiert. Neue Daten stehen im Einklang mit den europäischen Leitlinienempfehlungen.

Zell-Organisatoren unter Druck: Mechanismen des embryonalen Zahnwachstums aufgedeckt

08.04.2024 Zahnmedizin Nachrichten

Der Aufbau von Geweben und Organen während der Embryonalentwicklung wird von den Zellen bemerkenswert choreografiert. Für diesen Prozess braucht es spezielle sogenannte „Organisatoren“. In einer aktuellen Veröffentlichung im Fachjournal Nature Cell Biology berichten Forschende durch welchen Vorgang diese Organisatoren im Gewebe entstehen und wie sie dann die Bildung von Zähnen orchestrieren.

Die Oralprophylaxe & Kinderzahnheilkunde umbenannt

11.03.2024 Kinderzahnmedizin Nachrichten

Infolge der Umbenennung der Deutschen Gesellschaft für Kinderzahnheilkunde in Deutsche Gesellschaft für Kinderzahnmedizin (DGKiZ) wird deren Mitgliederzeitschrift Oralprophylaxe & Kinderzahnheilkunde in Oralprophylaxe & Kinderzahnmedizin umbenannt. Aus diesem Grunde trägt die erste Ausgabe in 2024 erstmalig den neuen Titel.

Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Zahnmedizin und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen
Bildnachweise